PCVX: VAX-31 cleared OPUS-1 endpoints as pro forma liquidity reached ~$3.4B

Vaxcyte (PCVX) reported Q3 GAAP EPS of -$1.99, beating estimates by $0.15. The company had $2.26B in cash and investments as of September 30, 2026, down from $2.44B at the end of 2025, before a $1.1B offering in October 2026.

Vaxcyte reported a net loss of $297M in 3Q 2026, up 39.6% YoY, with EPS at $(1.99). The company advanced vaccine trials, with VAX-31 meeting primary endpoints in Phase 3. R&D costs rose 54% YoY due to manufacturing and trial activities.

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.

Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.

Cantor Fitzgerald reiterated an Overweight rating on Vaxcyte (PCVX) with a $120 price target, citing OPUS-1 data and $1B financing. The firm raised adult success probability to 90% and noted potential upside to $90. The stock has declined 10% in a week but gained 50% over a year. Multiple analysts updated targets post-trial results.